Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 362

1.

Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.

Hyman DM, Zhou Q, Iasonos A, Grisham RN, Arnold AG, Phillips MF, Bhatia J, Levine DA, Aghajanian C, Offit K, Barakat RR, Spriggs DR, Kauff ND.

Cancer. 2012 Aug 1;118(15):3703-9. doi: 10.1002/cncr.26655. Epub 2011 Dec 2.

PMID:
22139894
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.

Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W.

JAMA. 2011 Oct 12;306(14):1557-65. doi: 10.1001/jama.2011.1456. Erratum in: JAMA. 2012 Jan 25;307(4):363.

PMID:
21990299
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G.

J Clin Oncol. 2012 Jul 20;30(21):2654-63. doi: 10.1200/JCO.2011.39.8545. Epub 2012 Jun 18. Erratum in: J Clin Oncol. 2012 Nov 20;30(33):4180.

PMID:
22711857
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.

Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, Saigo PE, Almadrones LA, Barakat RR, Brown CL, Chi DS, Curtin JP, Poynor EA, Hoskins WJ.

JAMA. 2000 May 3;283(17):2260-5.

PMID:
10807385
[PubMed - indexed for MEDLINE]
5.

Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.

Piek JM, Torrenga B, Hermsen B, Verheijen RH, Zweemer RP, Gille JJ, Kenemans P, van Diest PJ, Menko FH.

Fam Cancer. 2003;2(2):73-8.

PMID:
14574155
[PubMed - indexed for MEDLINE]
6.

Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival.

Liu J, Cristea MC, Frankel P, Neuhausen SL, Steele L, Engelstaedter V, Matulonis U, Sand S, Tung N, Garber JE, Weitzel JN.

Cancer Genet. 2012 Jan-Feb;205(1-2):34-41. doi: 10.1016/j.cancergen.2012.01.008.

PMID:
22429596
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.

Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB, Gore ME.

J Clin Oncol. 2008 Dec 1;26(34):5530-6. doi: 10.1200/JCO.2008.16.1703. Epub 2008 Oct 27.

PMID:
18955455
[PubMed - indexed for MEDLINE]
Free Article
8.

Improved survival in women with BRCA-associated ovarian carcinoma.

Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY.

Cancer. 2003 May 1;97(9):2187-95.

PMID:
12712470
[PubMed - indexed for MEDLINE]
Free Article
9.

Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.

McLaughlin JR, Rosen B, Moody J, Pal T, Fan I, Shaw PA, Risch HA, Sellers TA, Sun P, Narod SA.

J Natl Cancer Inst. 2013 Jan 16;105(2):141-8. doi: 10.1093/jnci/djs494. Epub 2012 Dec 20.

PMID:
23257159
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD 2nd, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broaddus RR, Lanchbury JS, Lu KH, Mills GB.

J Clin Oncol. 2010 Aug 1;28(22):3570-6. doi: 10.1200/JCO.2009.27.2997. Epub 2010 Jul 6.

PMID:
20606085
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.

Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT.

Gynecol Oncol. 2005 May;97(2):457-67.

PMID:
15863145
[PubMed - indexed for MEDLINE]
12.

Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.

Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ.

Eur J Cancer. 2013 Jan;49(1):132-41. doi: 10.1016/j.ejca.2012.07.021. Epub 2012 Aug 21.

PMID:
22921157
[PubMed - indexed for MEDLINE]
13.

Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations.

Lacour RA, Westin SN, Meyer LA, Wingo SN, Schorge JO, Brooks R, Mutch D, Molina A, Sutphen R, Barnes M, Elder J, Teoh D, Powell CB, Choubey V, Blank S, Macdonald HR, Brady MF, Urbauer DL, Bodurka D, Gershenson DM, Lu KH.

Gynecol Oncol. 2011 May 1;121(2):358-63. doi: 10.1016/j.ygyno.2010.12.354. Epub 2011 Jan 28.

PMID:
21276604
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.

Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Australian Ovarian Cancer Study Management Group.

J Natl Cancer Inst. 2008 Nov 5;100(21):1519-29. doi: 10.1093/jnci/djn345. Epub 2008 Oct 28.

PMID:
18957670
[PubMed - indexed for MEDLINE]
Free Article
15.

Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.

Casey MJ, Bewtra C.

Fam Cancer. 2004;3(3-4):265-81. Review.

PMID:
15516851
[PubMed - indexed for MEDLINE]
16.

Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.

Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR.

J Clin Oncol. 2008 Mar 10;26(8):1331-7. doi: 10.1200/JCO.2007.13.9626. Epub 2008 Feb 11.

PMID:
18268356
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.

Casey MJ, Bewtra C, Lynch HT, Snyder C, Stacy M, Watson P.

Fam Cancer. 2013 Dec;12(4):719-40. doi: 10.1007/s10689-013-9651-x.

PMID:
23666231
[PubMed - indexed for MEDLINE]
18.

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K.

N Engl J Med. 2002 May 23;346(21):1609-15. Epub 2002 May 20.

PMID:
12023992
[PubMed - indexed for MEDLINE]
Free Article
19.

Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.

Zweemer RP, Shaw PA, Verheijen RM, Ryan A, Berchuck A, Ponder BA, Risch H, McLaughlin JR, Narod SA, Menko FH, Kenemans P, Jacobs IJ.

J Clin Pathol. 1999 May;52(5):372-5.

PMID:
10560359
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.

Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC.

PLoS One. 2013 Nov 12;8(11):e80023. doi: 10.1371/journal.pone.0080023. eCollection 2013.

PMID:
24265793
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk